We are live on ! Find out more
PI

Pharmstandard International Portfolio holdings

AUM $29M
1-Year Est. Return 3.25%
This Fund
S&P 500
This Quarter Est. Return
-8.16%
1 Year Est. Return
+3.25%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$24.9M
AUM Growth
-$14.9M
Cap. Flow
-$5.61M
Cap. Flow %
-22.51%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
4
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
ALNA
Allena Pharmaceuticals
ALNA
+$2.29M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$1.78M
3
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$1.4M
4
TARA icon
Protara Therapeutics
TARA
+$140K

Sector Composition

Rank Sector Weight
1 Healthcare 99.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNA
1
DELISTED
Allena Pharmaceuticals
ALNA
$11.4M 45.89%
878,131
-159,136
-15% -$2.29M
PTGX icon
2
Protagonist Therapeutics
PTGX
$8.71B
$5.04M 20.23%
750,632
-231,638
-24% -$1.78M
JNCE
3
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$4.33M 17.36%
565,063
-97,000
-15% -$1.4M
TARA icon
4
Protara Therapeutics
TARA
$229M
$3.94M 15.8%
40,195
-1,503
-4% -$140K
ARGS
5
DELISTED
Argos Therapeutics, Inc.
ARGS
$136K 0.55%
826,153
– –
ARGS
6
CALL
DELISTED
Argos Therapeutics, Inc.
ARGS
$42K 0.17%
256,030
– –

Similar funds

IP
Ironsides Partners Boston, Massachusetts $27.7M AUM 1.11% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
MC
Marcus Capital Northbrook, Illinois $34.3M AUM 30.44% 1-Year Est. Return
RIA
Rocaton Investment Advisors Norwalk, Connecticut $36.6M AUM 10.31% 1-Year Est. Return
FC
Flaherty & Crumrine Pasadena, California $19.8M AUM 3.53% 1-Year Est. Return
WFC
West Face Capital Toronto, Ontario, Canada $16.6M AUM 18.79% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
DCM
Dearborn Capital Management Chicago, Illinois $41.6M AUM 2.79% 1-Year Est. Return

Pharmstandard International's Q2 2018 Portfolio in Review

As of Q2 2018, Pharmstandard International held 6 positions worth $24.9M, down 37% from $39.8M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Pharmstandard International withdrew a net $5.61M in Q2 2018, reducing 4 holdings. Its largest reduction was Allena Pharmaceuticals, cutting an estimated $2.29M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

  • Pharmstandard International's biggest Q2 2018 reduction was Allena Pharmaceuticals, cutting an estimated $2.29M.
  • Pharmstandard International's ten largest holdings make up 100% of its $24.9M portfolio in Q2 2018.
  • Pharmstandard International opened 0 new positions and closed 0 in Q2 2018.
  • Pharmstandard International's portfolio value fell 37% quarter-over-quarter to $24.9M.

Based on Pharmstandard International's 13F filing for Q2 2018, filed 14 Aug 2018.